Stellar price is trading near $0.26, up 2.09% over the past 24 hours, as the asset extends its intraday recovery despite broader higher-time-frame weakness.Stellar price is trading near $0.26, up 2.09% over the past 24 hours, as the asset extends its intraday recovery despite broader higher-time-frame weakness.

Stellar News 2025: Holds $0.26 After Strong Intraday Uptrend as Daily Charts Warn of Persistent Macro Weakness

2025/11/28 03:40
3 min read

The market has shown renewed short-term bullish structure, but long-term technical indicators still point to caution as momentum remains fragile.

XLM Breaks Out of Short-Term Downtrend and Forms Clear Intraday Uptrend

From the 22nd onward, the coin shifted from a mild downtrend into a well-defined intraday uptrend, climbing from the $0.22 region toward $0.26. The structure of higher highs and higher lows signals that buyers have regained control following the earlier selloff. This trend is further supported by sustained dip-buying interest, with recent candles closing near the upper end of the range, reflecting strong short-term demand.

Source: Open Interest

The recovery momentum was most pronounced during the rally into the 24th, where bullish pressure intensified and confirmed the intraday breakout. While the broader macro trend remains uncertain, the recent price behavior shows clear tactical strength and improving market sentiment in the lower timeframes.

Open Interest Rises During the Rally, Then Eases as Price Consolidates

Aggregated open interest rose sharply during the breakout, particularly during the strong upward push on the 24th. This OI expansion, paired with rising price signals, fresh long positions entering the market, rather than short liquidations. Such alignment between growing interest and advancing price typically reflects trend confirmation and strengthening conviction among traders.

However, after OI peaked near the top of the range, it began to cool off while price stabilized around $0.26. This pattern indicates profit-taking or controlled de-leveraging, rather than aggressive short selling. As long as price holds above the key breakout region between $0.24 and $0.245, the intraday uptrend remains intact. A failure to defend this zone would suggest that the long build-up is unwinding more decisively.

XLM at $0.26 with $8.33B Market Cap

According to BraveNewCoin, the coin is currently priced at $0.26 with a market cap of $8.33 billion and a 24-hour volume of $208.5 million. The circulating supply stands at 32.31 billion tokens, placing the crypto at Rank 24 globally.

The modest 2% daily gain aligns with its recent intraday recovery, though the asset still trades well below the multi-month resistance zone near $0.30. While short-term sentiment is improving, long-term structure remains under pressure.

Daily Chart Still Shows Macro Downtrend Despite Intraday Strength

From a higher-time-frame perspective, XLM remains stuck in a broader downtrend. The daily chart shows a consistent pattern of lower highs and lower lows, and every attempted bounce toward the $0.30 resistance has faded quickly. Despite the recent intraday push, the overall trend remains controlled by sellers.

Source: TradingView

The MACD sits at –0.0131, below the signal line at –0.0126. Although the histogram is neutral, momentum remains firmly in negative territory. This suggests that while selling pressure has slowed, buyers have not yet generated a convincing trend reversal.

The Chaikin Money Flow (CMF) at –0.08 indicates mild capital outflow and minimal accumulation. Even with the intraday strength, there is no clear sign of sustained buying interest on the daily chart.

Market Opportunity
NEAR Logo
NEAR Price(NEAR)
$1.0577
$1.0577$1.0577
-0.19%
USD
NEAR (NEAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03